scholarly article | Q13442814 |
P356 | DOI | 10.1002/HON.2370 |
P698 | PubMed publication ID | 27878835 |
P50 | author | Guillaume Cartron | Q38803376 |
Anne Quinquenel | Q61196720 | ||
Anne-Sophie Michallet | Q87908815 | ||
P2093 | author name string | Pierre Morel | |
Stéphane Lepretre | |||
Marie Christine Béné | |||
Véronique Leblond | |||
Florence Cymbalista | |||
Pierre Feugier | |||
Bruno Cazin | |||
Jehan Dupuis | |||
Loic Ysebaert | |||
Richard Lemal | |||
Phi Linh Nguyen-Thi | |||
Cécile Tomowiak | |||
Godelieve Meunier | |||
Thérèse Aurran | |||
Annie Brion | |||
Daniel Ré | |||
Marie Sarah Dilhuydy | |||
P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study | Q33343164 | ||
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials | Q33695990 | ||
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database | Q33846793 | ||
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis | Q34282319 | ||
Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry | Q34359352 | ||
Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale | Q34425278 | ||
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 | Q34879367 | ||
Management and geriatric assessment of cancer in the elderly | Q35782952 | ||
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia | Q36843749 | ||
International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer | Q36925135 | ||
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia | Q37059754 | ||
Treatment of elderly patients with chronic lymphocytic leukemia | Q37386705 | ||
Multidimensional geriatric evaluation for older cancer patients as a clinical and research tool | Q37501072 | ||
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia | Q37517160 | ||
Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study | Q37879960 | ||
Chronic lymphocytic leukemia in less fit patients: "slow-go". | Q37903038 | ||
Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices | Q37940136 | ||
Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers | Q38169637 | ||
Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia | Q38248969 | ||
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial | Q38424831 | ||
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century | Q40118546 | ||
Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. | Q43423234 | ||
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization | Q43643159 | ||
Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? | Q43737974 | ||
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience | Q44079638 | ||
Comorbidity and functional status are independent in older cancer patients | Q44747457 | ||
Development and validation of a prognostic index for 4-year mortality in older adults. | Q45975392 | ||
ESH–SIOG International Conference on Haematological Malignancies in the Elderly | Q51742814 | ||
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. | Q51927016 | ||
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. | Q52644149 | ||
Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. | Q53087437 | ||
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 | ||
P433 | issue | 4 | |
P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
P304 | page(s) | 671-678 | |
P577 | publication date | 2016-11-22 | |
P1433 | published in | Hematological Oncology | Q15762617 |
P1476 | title | First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study | |
P478 | volume | 35 |
Q58035743 | Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study | cites work | P2860 |
Search more.